{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-042291","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2024-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.595027+00:00","generated_at":"2026-06-04T01:46:34.228084+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Adaptive Biotech Q1 prelim rev ~$41-43M (+12% YoY); CFO Peterson departs, Piskel named","bullets":["Preliminary total Q1 2024 revenue of ~$41-43M, up ~12% vs Q1 2023.","MRD revenue ~$31-32M, up ~47% YoY; Immune Medicine revenue implied by difference.","Strategic review concludes: run MRD and Immune Medicine internally with separate resources and segment reporting.","CFO Tycho Peterson departs; Kyle Piskel (Principal Accounting Officer, 8-yr tenure) appointed full-time CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-042291","json":"https://secwatch.observer/filing/0000950170-24-042291.json","markdown":"https://secwatch.observer/filing/0000950170-24-042291.md","text":"https://secwatch.observer/filing/0000950170-24-042291.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000095017024042291/0000950170-24-042291-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000095017024042291/adpt-20240402.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:46:34.228084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dbee83e3436944d4d5101d754165d6a384679282","claim":"Adaptive Biotechnologies Corp reported first quarter ended March 31, 2024 results: revenue approximately $41 to $43 million.","evidence_excerpt":"process and outcome of the strategic review during the conference call this afternoon. First Quarter 2024 Preliminary Unaudited Revenue Results • Total revenue of approximately $41 to $43 million for the first quarter of 2024, an increase of approximately 12% compared to the first quarter of 2023. • MRD revenue of approximately $31 to $32 million for the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1478320/000095017024042291/0000950170-24-042291-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"approximately $41 to $43 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}